Misonix, Inc. an international surgical device company, announced today the appointment of Patrick McBrayer to the Company's Board of Directors effective immediately. With more than 20 years of senior management experience in the healthcare industry, Patrick McBrayer has extensive relevant industry experience to the Misonix Board. Mr. McBrayer currently serves as President and Chief Executive Officer of AxioMed Spine Corporation, a leading, privately-held, developer of next generation technology for degenerative spine conditions.
Prior to AxioMed, Mr. McBrayer was Chief Executive Officer of Xylos Corporation, a medical biomaterials company. He is also a Founder of Transave Inc., a biotechnology company focused on the site-specific treatment of lung disease. Prior to joining Xylos, Mr. McBrayer served as President and CEO of Exogen, Inc., a company focused on the non-invasive treatment of musculoskeletal injury and disease, which was acquired by Smith & Nephew, Inc. in 1999.
Previously, Mr. McBrayer was President and CEO of Osteotech, Inc., a worldwide leader in tissue technology. In both companies, he was responsible for a number of private placements and both companies' public offerings and led these organizations to dominant market share positions. He received the Thomas Alva Edison Patent Award in 1998 for a biological implant for bone repair that is now a market-leading product. Prior to joining Osteotech, Mr. McBrayer held positions of increasing responsibility for Johnson & Johnson, Inc.
A 1974 graduate of the United States Military Academy (West Point), Mr. McBrayer served as an Infantry Officer Company Commander in the U.S. Army prior to beginning his business career. Mr. McBrayer has also served on West Point's Association of Graduates Board of Trustees.